AIM ImmunoTech (NYSE:AIM) Issues Quarterly Earnings Results

AIM ImmunoTech (NYSE:AIMGet Free Report) released its earnings results on Thursday. The company reported ($0.12) EPS for the quarter, reports. AIM ImmunoTech had a negative net margin of 16,123.32% and a negative return on equity of 191.38%. The business had revenue of $0.04 million for the quarter.

AIM ImmunoTech Trading Up 3.3 %

Shares of NYSE:AIM opened at $0.40 on Friday. AIM ImmunoTech has a 52-week low of $0.32 and a 52-week high of $0.75. The business’s 50 day moving average is $0.44 and its 200 day moving average is $0.44. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.14 and a quick ratio of 1.68.

Insider Buying and Selling

In other news, CEO Thomas K. Equels acquired 75,758 shares of the company’s stock in a transaction that occurred on Friday, March 15th. The shares were bought at an average price of $0.33 per share, with a total value of $25,000.14. Following the completion of the purchase, the chief executive officer now directly owns 716,455 shares in the company, valued at $236,430.15. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, CEO Thomas K. Equels bought 75,758 shares of the stock in a transaction on Friday, March 15th. The stock was bought at an average price of $0.33 per share, for a total transaction of $25,000.14. Following the completion of the acquisition, the chief executive officer now directly owns 716,455 shares in the company, valued at $236,430.15. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Stewart Appelrouth bought 90,910 shares of the stock in a transaction on Friday, March 15th. The shares were bought at an average price of $0.33 per share, with a total value of $30,000.30. Following the acquisition, the director now owns 239,765 shares of the company’s stock, valued at $79,122.45. The disclosure for this purchase can be found here. Insiders have bought a total of 335,603 shares of company stock valued at $120,464 over the last quarter. 0.02% of the stock is owned by corporate insiders.

About AIM ImmunoTech

(Get Free Report)

AIM ImmunoTech Inc, an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS).

Recommended Stories

Earnings History for AIM ImmunoTech (NYSE:AIM)

Receive News & Ratings for AIM ImmunoTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AIM ImmunoTech and related companies with MarketBeat.com's FREE daily email newsletter.